CheckMate 8HW final results: dual checkpoint inhibition in MSI-H/dMMR metastatic colorectal cancer
Annals of Oncology,
0.61
Overall survival hazard ratio vs nivolumab, all treatment lines
0.37
Overall survival hazard ratio vs chemotherapy, first line
Take-home
Final CheckMate 8HW results (68-month follow-up) demonstrate:
OS benefit vs nivolumab across all treatment lines (HR 0.61)
OS benefit vs chemotherapy in 1L (HR 0.37)
Sustained PFS and response advantages
No new safety signals
A significant step forward for immunotherapy in mCRC.
